Dark

IONS
Ionis Pharmaceuticals, Inc. Common Stock
stock NASDAQ

At Close

May 30, 2025 3:59:56 PM EDT

33.49USD+0.090%(+0.03)1,654,650

0.00Bid 0.00Ask 0.00Spread

Pre-market

May 27, 2025 8:36:30 AM EDT

34.61USD+3.430%(+1.15)0

After-hours

May 30, 2025 4:05:30 PM EDT

33.51USD0.000%(0.00)23,034

OverviewOptionsHistoricalExchangesShortsNews

Jan 31, 2022

08:52AM EST Benzinga Pro's Top 5 Stocks To Watch For Monday, Jan. 31, 2022: NFLX, BB, IONS, NXPI, EA Benzinga

07:47AM EST Pfizer Inc. (PFE) and Ionis Pharmaceuticals, Inc. (IONS) announced the discontinuation of the Pfizer-led clinical development program for vupanorsen, an investigational antisense therapy. Also, Pfizer will return development rights to vupanorsen to Ionis. RTTNews

07:16AM EST Pfizer And Ionis Announce Discontinuation Of Vupanorsen Clinical Development Program Benzinga

07:08AM EST Pfizer, Ionis Announce Discontinuation Of Vupanorsen Clinical Program For CV Risk Reduction And Hypertriglyceridemia RTTNews

07:05AM EST Pfizer and Ionis announce discontinuation of vupanorsen clinical development PR Newswire

Jan 24, 2022

09:26AM EST Ionis' Eplontersen Receives FDA Orphan Drug Status For Misfolded Protein Disorder Benzinga

07:28AM EST Ionis Pharmaceuticals, Inc. (IONS) announced Monday that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to eplontersen, an investigational antisense medicine for the treatment of people living with transthyretin-mediated amyloidosis, a systemic, progressive and fatal condition. RTTNews

07:19AM EST Ionis' Eplontersen Receives Orphan Drug Designation from the FDA Benzinga

07:13AM EST Ionis Pharma Announces Eplontersen Receives Orphan Drug Designation From FDA RTTNews

07:08AM EST Ionis' Eplontersen Receives Orphan Drug Designation from the FDA Benzinga

07:05AM EST Ionis announces eplontersen receives orphan drug designation from U.S. FDA PR Newswire

Jan 19, 2022

07:05AM EST business officer and Eric Bastings, M.D., as vice president, development strategy PR Newswire

Jan 18, 2022

05:09AM EST Ionis' Announced Partner Roche to Evaluate Tominersen for Huntington's Disease in New Phase 2 Trial Benzinga

01:38AM EST Ionis Pharmaceuticals, Inc. (IONS) said on Tuesday that its partner, Roche, is designing a new Phase 2 trial to evaluate tominersen, for Huntington's disease or HD, a rare genetic, progressive condition that causes the brain nerve cells to break down, leading to a disability. RTTNews

12:51AM EST Ionis' Partner Roche To Evaluate Tominersen For Huntington's Disease In New Phase 2 Trial RTTNews

12:05AM EST Ionis' partner to evaluate tominersen for Huntington's disease in new Phase 2 PR Newswire

Jan 5, 2022

07:05AM EST Ionis to present at 40th Annual J.P. Morgan Healthcare conference PR Newswire

Jan 4, 2022

08:07AM EST Biogen Licenses Global Rights To Develop, Commercialize RTTNews

07:35AM EST Biogen Exercises Option To Obtain From Ionis A Worldwide License To Develop BIIB115/ION306 RTTNews

07:34AM EST Biogen Exercises Option With Ionis To Develop And Commercialize Investigational ASO For SMA Benzinga

07:34AM EST -- BIIB115 is a preclinical investigational antisense oligonucleotide (ASO) that may have the potential for extended dosing intervals -- Biogen paid Ionis a $60 million one-time upfront payment GlobeNewswire Inc

07:30AM EST Biogen Exercises Option with Ionis to Develop and Commercialize Investigational PR Newswire

Jan 2, 2022

03:30PM EST The Week Ahead In Biotech (Jan 2-Jan. 8): Stray Clinical Readouts In Focus In Slow News Week Benzinga

Dec 29, 2021

02:45AM EST Ionis Pharmaceuticals, Inc. (IONS), a company focused on RNA-targeted therapies, on Wednesday unveiled the closing of the previously announced collaboration deal with AstraZeneca to develop and commercialize eplontersen, following expiration of the waiting period under the HSR Act. RTTNews

02:01AM EST Ionis and AstraZeneca close deal to develop and commercialize eplontersen PR Newswire

Dec 17, 2021

04:45AM EST SVB Leerink Maintains Market Perform on Ionis Pharmaceuticals, Lowers Price Target to $34 Benzinga

Dec 14, 2021

10:03AM EST Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2021 Benzinga

10:00AM EST Where Ionis Pharmaceuticals Stands With Analysts Benzinga

07:35AM EST William Blair Upgrades Ionis Pharmaceuticals to Outperform Benzinga

Dec 8, 2021

08:39AM EST SVB Leerink Maintains Market Perform on Ionis Pharmaceuticals, Lowers Price Target to $36 Benzinga

Dec 7, 2021

08:26AM EST The Daily Biotech Pulse: Acadia Jumps On Data, vTv Shelves Psoriasis Study, More Setback For Merck's HIV Program, Decision Day For Dar Benzinga

07:44AM EST Ionis, AstraZeneca Ink Licensing Pact For Eplontersen In Protein Misfolding Disorder Benzinga

04:41AM EST Ionis Announced Collaboration With AstraZeneca to Develop and Commercialize Eplontersen; Ionis to Receive $200M Upfront, Up to $485M in Development and Approval Milestones, Up to $2.9B in Sales-related Milestone Payments Benzinga

02:01AM EST Ionis and AstraZeneca to develop and commercialize eplontersen PR Newswire

Dec 2, 2021

03:04PM EST Ionis to hold virtual investor day event PR Newswire

Nov 24, 2021

06:57AM EST Ionis Pharmaceuticals Inc. (IONS) said Pfizer reported topline results from phase 2b clinical study of vupanorsen, formerly IONIS-ANGPTL3-LRx. RTTNews

06:34AM EST Ionis Says Pfizer Reports Topline Results From Phase 2b Study Of Vupanorsen On Non-HDL-C RTTNews

06:32AM EST Ionis Announces That Pfizer Reports Topline Results From Phase 2B Clinical Study Of Vupanorsen Benzinga

06:31AM EST Ionis announces that Pfizer reports topline results from Phase 2b clinical PR Newswire

Nov 18, 2021

01:31PM EST Ionis Pharma Reports Initiated Phase 3 Trial Program Of Donidalorsen In Patients With Hereditary Angioedema Benzinga

01:31PM EST Ionis initiates Phase 3 clinical program of donidalorsen in patients with PR Newswire

Nov 15, 2021

10:31AM EST Barron's Most Recent Picks And Pans: General Electric, Pfizer, Walt Disney And More Benzinga

Nov 12, 2021

07:05AM EST Ionis' antisense therapies to be featured at the American Heart Association PR Newswire

Nov 9, 2021

07:05AM EST Ionis to present at upcoming virtual investor conferences PR Newswire

Nov 7, 2021

07:05AM EST Phase 2 study results of Ionis' novel antisense treatment for hereditary PR Newswire

Nov 4, 2021

06:51AM EDT Needham Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $60 Benzinga

04:49AM EDT SVB Leerink Maintains Market Perform on Ionis Pharmaceuticals, Raises Price Target to $39 Benzinga

Nov 3, 2021

09:19AM EDT The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering Benzinga

09:15AM EDT Ionis Pharmaceuticals Q3 EPS $(0.34) Beats $(0.51) Estimate, Sales $133.00M Miss $158.38M Estimate Benzinga

09:10AM EDT Earnings Scheduled For November 3, 2021 Benzinga

07:24AM EDT Ionis Q3 Net Loss $82 Mln Vs. Net Loss $37 Mln Last Year RTTNews

07:02AM EDT Ionis reports third quarter 2021 financial results and recent business PR Newswire

Nov 2, 2021

10:50AM EDT Ionis Initiates Pivotal Phase 3 Study Of Olezarsen In Patients With Severe Hypertriglyceridemia Benzinga

07:05AM EDT Ionis initiates pivotal Phase 3 clinical study of olezarsen in patients with PR Newswire

Oct 31, 2021

02:24PM EDT The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline Benzinga

Oct 20, 2021

07:06AM EDT Ionis to hold third quarter 2021 financial results webcast PR Newswire

Oct 17, 2021

04:20PM EDT Ionis' partner Biogen provides update on tofersen Phase 3 VALOR study in PR Newswire

Oct 14, 2021

04:11PM EDT Biogen Highlights Topline Results From Tofersen Phase 3 Study, Its Open Label Extension In Superoxide Dismutase 1 Amyotrophic Lateral Sclerosis At American Neurological Association Meeting Benzinga

04:06PM EDT Topline Results from Tofersen Phase 3 Study and its Open Label GlobeNewswire Inc

Oct 12, 2021

08:25AM EDT Morgan Stanley Maintains Underweight on Ionis Pharmaceuticals, Lowers Price Target to $31 Benzinga

Oct 1, 2021

07:56AM EDT The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO Benzinga

Sep 30, 2021

07:43AM EDT The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug Benzinga

Sep 29, 2021

08:13AM EDT The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug Benzinga

Sep 15, 2021

07:30AM EDT Biogen Plans to Initiate Phase 3b Study Evaluating Potential GlobeNewswire Inc

Sep 3, 2021

07:05AM EDT Ionis to host ATTR symposium highlighting CARDIO-TTRansform Study at 3rd PR Newswire

Sep 2, 2021

07:05AM EDT Ionis to present at upcoming virtual investor conferences PR Newswire

Aug 24, 2021

07:06AM EDT PTC Therapeutics' Waylivra Scores Approval In Brazil For Genetic Disorder Benzinga

Aug 19, 2021

08:03AM EDT BMO Capital Maintains Outperform on Ionis Pharmaceuticals, Lowers Price Target to $68 Benzinga

Aug 5, 2021

05:59AM EDT SVB Leerink Maintains Market Perform on Ionis Pharmaceuticals, Lowers Price Target to $38 Benzinga

Aug 4, 2021

07:13AM EDT Ionis Reaffirms FY21 Sales Guidance $600M+, Net Loss Improved From Less Than $110M To Less Than $75M Benzinga

07:12AM EDT Ionis Pharmaceuticals Q2 EPS $(0.57) Beats $(0.58) Estimate, Sales $126.00M Miss $129.94M Estimate Benzinga

07:01AM EDT Ionis reports second quarter 2021 financial results and recent business PR Newswire

04:10AM EDT Earnings Scheduled For August 4, 2021 Benzinga

Aug 2, 2021

09:33AM EDT Ionis Pharmaceuticals Says Lp HORIZON Achieves 50% Enrollment In Trial To Assess Safety, Efficacy Of Pelacarsen In Reducing Recurrent Cardiovascular Events Benzinga

09:32AM EDT Lp HORIZON Achieves 50% Enrollment In Trial To Assess Efficacy Of Pelacarsen In Reducing Recurrent Cardiovascular Events RTTNews

09:31AM EDT Lp(a) HORIZON achieves 50% enrollment in trial to assess the safety and PR Newswire

Jul 29, 2021

07:54AM EDT Ionis Completes Enrollment In Pivotal NEURO-TTRansform Study Of Eplontersen Benzinga

Jul 26, 2021

04:38PM EDT Biogen And Ionis Report Positive Topline Clinical Data On Investigational Alzheimer's Disease Treatment At AAIC RTTNews

04:38PM EDT Biogen And Ionis Highlight Presentation Of Topline Data From Phase 1b Study Of BIIB080/IONIS-MAPTRx Showing Drug Met Safety And Tolerability Objective At AAIC Benzinga

04:35PM EDT Biogen and Ionis report positive topline clinical data on investigational PR Newswire

Jul 25, 2021

10:05AM EDT The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More Benzinga

Jul 21, 2021

07:05AM EDT Ionis to hold second quarter 2021 financial results webcast PR Newswire

Jul 16, 2021

08:52AM EDT Morgan Stanley Maintains Underweight on Ionis Pharmaceuticals, Lowers Price Target to $33 Benzinga

Jul 14, 2021

07:48AM EDT The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues Benzinga

Jul 13, 2021

08:06AM EDT Bicycle, Ionis To Develop Targeted Oligonucleotide Therapeutics Benzinga

08:05AM EDT The Daily Biotech Pulse: Equillium Issues Positive Regulatory Update, Biogen In-Licenses Multiple Sclerosis Drug, Aridis Releases COVID-19 Antibody Cocktail Data Benzinga

07:00AM EDT Bicycle Therapeutics Enters Exclusive License And Collaboration Agreement With Ionis To Develop Targeted Oligonucleotide Therapeutics; Bicycle To Receive $45M Upfront Payment And Is Eligible For Milestone Payments And Royalties Benzinga

07:00AM EDT Ionis enters exclusive licensing agreement with Bicycle Therapeutics aimed at PR Newswire

Jun 14, 2021

04:05PM EDT Ionis' Chief Scientific Officer C. Frank Bennett, Ph.D., receives Gabbay Award PR Newswire

Jun 10, 2021

06:05PM EDT Ionis' antisense therapies in ATTR amyloidosis to be featured at 2021 PNS PR Newswire

07:30AM EDT New Data at Cure SMA 2021 Highlight the Long-Term Efficacy of GlobeNewswire Inc

Jun 8, 2021

09:17AM EDT The Daily Biotech Pulse: Hookipa, PDS Biotech Report Positive Data, Ironwood CFO To Depart, Decision Day For Vertex Benzinga

Jun 4, 2021

09:39AM EDT The Daily Biotech Pulse: Merck, AstraZeneca, Novartis Among Early Presenters At ASCO, Sanofi Strikes Breast Cancer Study Pact Benzinga

Jun 2, 2021

08:00PM EDT Ionis announces changes to its board of directors at annual meeting of PR Newswire

May 28, 2021

08:02AM EDT The Daily Biotech Pulse: Biohaven, Bristol-Myers Squibb Snag FDA Approvals, Iterum UTI Drug Review On Track, Centessa Pharmaceuticals Debuts On Nasdaq Benzinga

May 27, 2021

08:24AM EDT The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs Benzinga

May 26, 2021

07:33AM EDT The Daily Biotech Pulse: Nabriva Jumps On Data, Larimar Wilts After Study Put On Hold, Travere To Delay Regulatory Filing Benzinga

07:05AM EDT Ionis to present at upcoming investor conferences PR Newswire

May 20, 2021

08:27AM EDT The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Order Flow Abounds, Voyager CEO, CMO To Depart, Decision Day For Bristol-Myers Squibb, ASCO Abstracts Move Stocks Benzinga

May 14, 2021

06:26AM EDT SVB Leerink Maintains Market Perform on Ionis Pharmaceuticals, Raises Price Target to $41 Benzinga

May 12, 2021

08:57AM EDT The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron Benzinga

May 11, 2021

07:54AM EDT The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings Benzinga

May 7, 2021

11:11AM EDT Analyst Ratings for Ionis Pharmaceuticals Benzinga

10:42AM EDT UBS Upgrades Ionis Pharmaceuticals to Neutral, Raises Price Target to $37.5 Benzinga

07:40AM EDT The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs Benzinga

May 6, 2021

08:36AM EDT Morgan Stanley Maintains Underweight on Ionis Pharmaceuticals, Lowers Price Target to $35 Benzinga

07:49AM EDT The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom Benzinga

07:06AM EDT Ionis to present at upcoming investor conferences PR Newswire

May 5, 2021

04:06PM EDT Ionis to host 2021 virtual annual meeting of stockholders PR Newswire

08:51AM EDT Ionis Pharma Says On Track To Achieve 2021 Guidance RTTNews

07:43AM EDT The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues Benzinga

07:21AM EDT Ionis Says Is On Track To Achieve FY21 Guidance Benzinga

07:21AM EDT Ionis Pharmaceuticals Q1 EPS $(0.64) Misses $(0.53) Estimate, Sales $85.00M Down From $133.00M YoY Benzinga

07:01AM EDT Ionis reports first quarter 2021 financial results and recent business PR Newswire

04:16AM EDT Earnings Scheduled For May 5, 2021 Benzinga

May 4, 2021

09:16AM EDT Cathie Wood Loads Up More On Alibaba Rivals Pinduoduo, JD Also Adds Skillz Benzinga

Apr 30, 2021

10:19AM EDT Cathie Wood Piles Up Teladoc As Shares Slump On Q1 Miss, Also Adds More Tesla Benzinga

Apr 21, 2021

07:05AM EDT Ionis to hold first quarter 2021 financial results webcast PR Newswire

Apr 20, 2021

08:07AM EDT The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex Benzinga

07:26AM EDT Ionis Pharma Initiates Pivotal Clinical Study Of ION373 In Patients With Alexander Disease RTTNews

07:09AM EDT Ionis Initiates Pivotal Clinical Study Of ION373 In Alexander Disease Benzinga

07:05AM EDT Ionis initiates pivotal clinical study of novel antisense medicine to treat PR Newswire

Apr 19, 2021

10:41AM EDT Morgan Stanley Maintains Underweight on Ionis Pharmaceuticals, Lowers Price Target to $38 Benzinga

10:18AM EDT Stocks That Hit 52-Week Lows On Monday Benzinga

07:30AM EDT -- Initial findings from the DEVOTE study suggest no new safety concerns and support continued development of a higher dose of SPINRAZA (nusinersen) -- Additional research reinforces the potential of biomarkers and highlights new digital tools that may help guide future treatment approaches and decisions for people with SMA GlobeNewswire Inc

Apr 14, 2021

07:51AM EDT The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead Benzinga

Apr 13, 2021

08:16AM EDT The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug Benzinga

Apr 8, 2021

07:07AM EDT Ionis Pharma Prices $550.0 Mln Of 0% Convertible Senior Notes Due 2026 In A Private Placement RTTNews

07:05AM EDT Ionis prices private placement of convertible senior notes PR Newswire

Apr 7, 2021

07:58AM EDT The Daily Biotech Pulse: FibroGen Fudges Safety Data, Novartis Strikes Cancer Drug Collaboration, Immutep Gains On Patent Award Benzinga

07:15AM EDT Ionis Axes Akcea's 70% Workforce Under Restructuring Plan Benzinga

Apr 6, 2021

04:37PM EDT Ionis announces proposed private placement of convertible notes PR Newswire

12:17PM EDT Why Scholar Rock Shares Dropped Despite Positive Apitegromab Data In Spinal Muscular Atrophy Benzinga

09:44AM EDT Ionis Antisense Oligonucleotides To Be Evaluated With Progenity's Drug Delivery System Benzinga

Apr 5, 2021

07:54AM EDT Ionis Pharmaceuticals, Inc. (IONS) has begun the late-stage study of its investigational drug, ION363 in patients with amyotrophic lateral sclerosis (ALS),the company said in a release. RTTNews

07:10AM EDT Ionis Initiates Phase 3 Trial Of Novel Antisense Medicine To Treat Leading Cause Of Juvenile-Onset ALS Benzinga

07:07AM EDT Ionis Pharma Initiates Phase 3 Trial Of Novel Antisense Medicine To Treat Leading Cause Of Juvenile-onset ALS RTTNews

07:05AM EDT Ionis initiates Phase 3 trial of novel antisense medicine to treat leading PR Newswire

Mar 29, 2021

11:30AM EDT Ionis Pharma's Ligand-Conjugated Antisense Hits Primary Endpoint Goal In Hereditary Angioedema Study Benzinga

07:16AM EDT Ionis Reports Positive Topline Phase 2 Study Results Of Novel Antisense Treatment For Hereditary Angioedema RTTNews

07:10AM EDT Ionis Announces Phase 2 Study Of IONIS-PKK-LRx Met Its Primary And Secondary Endpoint Benzinga

07:05AM EDT Ionis reports positive topline Phase 2 study results of its novel antisense PR Newswire

Mar 26, 2021

07:28AM EDT The Daily Biotech Pulse: FDA Nod For Astellas, Seagen, Gilead Get Positive Regulatory Tidings From Europe, 3 IPOs Benzinga

07:06AM EDT Ionis to present at upcoming investor conferences PR Newswire

Mar 23, 2021

09:29AM EDT BMO Capital Maintains Outperform on Ionis Pharmaceuticals, Lowers Price Target to $76 Benzinga

08:18AM EDT The Daily Biotech Pulse: FDA Approvals For Merck, Pacira And Zealand, Roche-Regeneron Ace Late-Stage COVID-19 Study, AlloVir Appoints Gilead Virology Chief As CEO Benzinga

08:01AM EDT Needham Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $86 Benzinga

07:52AM EDT Morgan Stanley Maintains Underweight on Ionis Pharmaceuticals, Lowers Price Target to $43 Benzinga

06:54AM EDT Ionis Pharma Stock Is Trading Lower After Roche Drops Huntington's Disease Trial With Tominersen Benzinga

06:26AM EDT Ionis Pharmaceuticals Awarded U.S. Patent #10,954,519 'Compounds and methods for modulation of dystrophia myotonica-protein kinase (DMPK) expression' Benzinga

05:40AM EDT SVB Leerink Maintains Market Perform on Ionis Pharmaceuticals, Lowers Price Target to $36 Benzinga

01:31AM EDT AZN's COVID-19 Jab Shows 79% Efficacy, ZEAL Wins FDA RTTNews

Mar 22, 2021

04:07PM EDT Windtree Therapeutics Announces Proposed Public Offering Of Common Stock, Warrants; Size, Price Not Disclosed Benzinga

04:03PM EDT Ionis Says Co's Partner Provides Update On Clinical Studies Evaluating Tominersen Benzinga

04:01PM EDT Ionis' partner provides update on clinical studies evaluating tominersen PR Newswire

04:01PM EDT Ionis Pharmaceuticals Shares Halted, News Pending Benzinga

Mar 8, 2021

08:46AM EST TRACON Pharmaceuticals Announces Appointment of Lisa GlobeNewswire Inc

Mar 1, 2021

07:05AM EST Ionis establishes new grant program to advance research and understanding of PR Newswire

Feb 25, 2021

09:01AM EST Morgan Stanley Maintains Underweight on Ionis Pharmaceuticals, Raises Price Target to $50 Benzinga

Feb 24, 2021

07:30AM EST The Daily Biotech Pulse: Bausch Calls Truce With Icahn, Pfizer's Brain Inflammation Vaccine Gets Priority Review, BriaCell IPO Benzinga

07:23AM EST Ionis Pharmaceuticals: Q4 Earnings Insights Benzinga

07:17AM EST Ionis Q4 Loss/Shr $2.44 Vs EPS $1.28 Last Year RTTNews

07:16AM EST Ionis Pharmaceuticals Q4 Adj. Net Income $103M vs $296M In Same Qtr. Last Year, Sales $290.00M Beat $274.48M Estimate Benzinga

07:01AM EST Ionis reports fourth quarter and full year 2020 financial results and recent PR Newswire

03:35AM EST Earnings Scheduled For February 24, 2021 Benzinga

Feb 19, 2021

07:05AM EST Ionis to present at upcoming investor conferences PR Newswire

Feb 11, 2021

07:05AM EST Ionis to hold 2020 financial results webcast PR Newswire

Jan 28, 2021

07:28PM EST CORRECTION: Cathie Wood's ARK Invests' Stock Purchases For Thursday, Jan. 28, 2021: RPTX, ACCD, CDXS, IONS, NVS, FATE, TSLA, EXPC, TER, SKLZ Benzinga

Jan 27, 2021

07:36AM EST The Daily Biotech Pulse: Sorrento, Immutep Surge On COVID-19 Study Data, T2 Biosystems Sinks On Preannouncement Benzinga

Jan 26, 2021

08:07AM EST The Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market Benzinga

Jan 8, 2021

08:07AM EST Biogen Begins Phase 4 Study Of SPINRAZA In Patients With RTTNews

07:31AM EST Biogen Announces First Patient Treated in RESPOND Study Evaluating Benefit of SPINRAZA in Patients Treated With Zolgensma Benzinga

07:30AM EST Biogen Announces First Patient Treated in RESPOND Study Evaluating GlobeNewswire Inc

Jan 7, 2021

05:30PM EST Ionis appoints Eugene Schneider, M.D., as executive vice president and chief PR Newswire

Dec 17, 2020

06:30PM EST Stanley T. Crooke, Ph.D., M.D, to retire from Ionis to focus on his scientific PR Newswire

Dec 8, 2020

09:45PM EST Ionis Pharmaceuticals Says Positioned For Strong 2021 And Beyond RTTNews

09:15PM EST Ionis highlights achievements, commercial strategy and technology advancements PR Newswire

Dec 7, 2020

12:13PM EST Ionis Pharmaceuticals Option Alert: Jul 16 $65 Calls Sweep (8) near the Ask: 100 @ $3.601 vs 6 OI; Ref=$51.29 Benzinga

Dec 2, 2020

07:05AM EST Ionis to participate in virtual fireside chat at BMO 2020 Growth and ESG PR Newswire

Dec 1, 2020

05:12PM EST Ionis Announces Initiation Of The Global Phase 3 BALANCE Study For ACKEA-APOCIII-LRX In Patients With Familial Chylomicronemia Syndrome Benzinga

05:10PM EST AKCEA-APOCIII-LRX in patients with familial chylomicronemia syndrome PR Newswire

07:05AM EST Ionis to hold virtual investor day event PR Newswire

Nov 30, 2020

05:17PM EST Ionis Pharma Highlights Initiation By AstraZeneca Of Phase 2b Study Of Its Antisense Medicien Targeting PCSK9 To Lower LDL-Chloesterol Benzinga

05:15PM EST Ionis announces AstraZeneca's initiation of the Phase 2b clinical study of its PR Newswire

Nov 23, 2020

05:15PM EST Ionis announces third investigational antisense medicine to treat nonalcoholic PR Newswire

Nov 13, 2020

07:24AM EST Ionis Pharma Reports Promising New Data For Antisense Medicine Targeting PCSK9 Presented At AHA RTTNews

07:14AM EST Ionis Pharmaceuticals Highlights Presentation Of ION449 Data At American Heart Association Scientific Sessions 2020 Benzinga

07:05AM EST Promising new data for Ionis' antisense medicine targeting PCSK9 presented at PR Newswire

Nov 12, 2020

07:12AM EST Ionis Pharmaceuticals Announces Upcoming Presentations At AHA Scientific Sessions Nov. 13-17 Benzinga

07:05AM EST Ionis' pioneering antisense technology to be featured in multiple presentations PR Newswire

Nov 10, 2020

07:05AM EST Ionis' antisense technology to be featured during virtual RNA at the Bench and PR Newswire

Nov 9, 2020

07:05AM EST Ionis to present at upcoming virtual investor conferences PR Newswire

Nov 5, 2020

08:17AM EST Morgan Stanley Maintains Underweight on Ionis Pharmaceuticals, Lowers Price Target to $49 Benzinga

04:10AM EST SVB Leerink Maintains Market Perform on Ionis Pharmaceuticals, Lowers Price Target to $50 Benzinga

Nov 4, 2020

09:50AM EST Ionis Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q3 EPS and sales results. Benzinga

08:21AM EST The Daily Biotech Pulse: Alzheimer's Conference Underway, Biogen's Aducanumab Briefing Doc, Supernus Earnings Benzinga

07:32AM EST Ionis Q3 Loss/shr $0.22 Vs. EPS $0.18 Prior Year RTTNews

07:24AM EST Recap: Ionis Pharmaceuticals Q3 Earnings Benzinga

07:09AM EST Ionis Pharmaceuticals Q3 EPS $(0.22) Misses $(0.09) Estimate, Sales $160.00M Miss $182.14M Estimate Benzinga

07:01AM EST Ionis reports third quarter 2020 financial results and recent business PR Newswire

04:41AM EST Earnings Scheduled For November 4, 2020 Benzinga

Nov 3, 2020

06:01PM EST Ionis and Akcea Announce That Pfizer Has Initiated A Phase 2b Clinical Study Of Its Vupanorsen Benzinga

06:00PM EST Ionis and Akcea announce that Pfizer has initiated a Phase 2b clinical study of PR Newswire

Nov 1, 2020

09:40AM EST The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings Benzinga

Oct 30, 2020

07:01AM EDT Ionis and Akcea win prestigious Prix Galien Award for TEGSEDI(r) (inotersen) as PR Newswire

Oct 22, 2020

07:12AM EDT Ionis Announces First Patients Have Been Dosed In ION541 Trial For ALS Benzinga

07:05AM EDT Ionis' third novel antisense medicine for ALS, its first designed to treat a PR Newswire

Oct 21, 2020

07:05AM EDT Ionis to hold third quarter 2020 financial results webcast PR Newswire

Oct 15, 2020

12:18PM EDT Ionis Pharmaceuticals Option Alert: Apr 16 $55 Calls Sweep (16) near the Ask: 136 @ $5.0 vs 1200 OI; Earnings 11/4 Before Open [est] Ref=$48.11 Benzinga

11:27AM EDT Ionis Pharmaceuticals Shares Quiet; Co Granted FDA Orphan Drug Designation For Treatment Of Beta-Thalassemia Intermedia And Major Benzinga

07:15AM EDT Ionis Says Its IONIS-PKK-LR Antisense Medicine Being Evaluated In An Investigator-initiated Clinical Study Of Covid-19 Patients In Brazil Benzinga

07:05AM EDT Ionis antisense medicine being evaluated in an investigator-initiated clinical PR Newswire

Oct 13, 2020

12:33PM EDT /C O R R E C T I O N -- Ionis Pharmaceuticals, Inc./ PR Newswire

09:55AM EDT Morgan Stanley Maintains Underweight on Ionis Pharmaceuticals, Lowers Price Target to $50 Benzinga

07:05AM EDT Ionis' inhaled antisense medicine demonstrates potential as a novel treatment PR Newswire

Oct 12, 2020

09:01AM EDT Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics PR Newswire

Oct 11, 2020

06:35PM EDT IPO Outlook: Solar Power Company Array Technologies, Chinese Retailer Miniso Lead Possible 9 IPO Week Benzinga

Oct 8, 2020

02:26PM EDT Ionis Pharmaceuticals Receives Orphan Drug Designation For Treatment Of Lafora Diseases Benzinga

Oct 1, 2020

04:05PM EDT Ionis Chief Scientific Officer Frank Bennett receives Lifetime Achievement PR Newswire

06:06AM EDT Ionis And Genuity Science Announce Agreement Designed To Rapidly Translate Genomic Insights Into Therapeutics; Genuity Science Will Receive A Combination Of Upfront Payments And Development Milestones, Plus Product Royalties Benzinga

06:01AM EDT Ionis and Genuity Science announce agreement designed to rapidly translate PR Newswire

Sep 30, 2020

04:08PM EDT Ionis Announces Its Treatment For Alexander Disease Receives Orphan Drug Designation From The FDA Benzinga

04:05PM EDT Ionis treatment for Alexander disease receives orphan drug designation from PR Newswire

Sep 3, 2020

07:05AM EDT Ionis to present at upcoming virtual investor conferences PR Newswire

Sep 2, 2020

05:10PM EDT New England Journal of Medicine publishes study results evaluating Ionis PR Newswire

10:21AM EDT Benzinga's Top Upgrades, Downgrades For September 2, 2020 Benzinga

07:52AM EDT Benchmark Initiates Coverage On Ionis Pharmaceuticals with Hold Rating Benzinga

Sep 1, 2020

06:44AM EDT SVB Leerink Maintains Market Perform on Ionis Pharmaceuticals, Raises Price Target to $56 Benzinga

05:35AM EDT (AKCA) Alert: Johnson Fistel Investigates Proposed Sale of Akcea Therapeutics; PR Newswire

05:13AM EDT Needham Maintains Buy on Ionis Pharmaceuticals, Raises Price Target to $91 Benzinga

Aug 31, 2020

08:21PM EDT SHAREHOLDER ALERT: WeissLaw LLP Investigates Akcea Therapeutics, Inc. PR Newswire

07:28AM EDT Ionis Pharmaceuticals Inc. (IONS) said it enetred into a definitive agreement with its affiliate Akcea Therapeutics Inc. (AKCA) to acquire all of the outstanding shares of Akcea common stock it does not already own, about 24%, for $18.15 per share in cash, representing a total transaction value of about $500 million. RTTNews

06:57AM EDT Ionis To Buy Remaining 24% Of Common Stock Of Akcea It Does Not Already Own For $18.15/Shr Cash RTTNews

06:56AM EDT Akcea Therapeutics to be Acquired by Ionis Pharmaceuticals for $18.15/Share in Cash Benzinga

06:55AM EDT Ionis Pharmaceuticals to acquire remaining stake in Akcea Therapeutics PR Newswire

Aug 29, 2020

04:02AM EDT Positive Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L(Rx)) Presented at PR Newswire

03:30AM EDT Positive Phase 2 Clinical Data of AKCEA-APOCIII-L(Rx) Presented at ESC Congress PR Newswire

Aug 26, 2020

07:05AM EDT Ionis Pharmaceuticals to hold cardio-renal franchise webcast PR Newswire

Aug 24, 2020

07:10AM EDT Akcea and Ionis to Present Phase 2 Clinical Data of Vupanorsen at ESC Congress 2020 Benzinga

07:01AM EDT Akcea and Ionis to Present Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L PR Newswire

Aug 18, 2020

07:21AM EDT Akcea, Ionis To Present Phase 2 Results Of AKCEA-APOCIII-L(Rx) In Late-Breaking Presentation At ESC Congress 2020 Benzinga

07:01AM EDT Akcea and Ionis to Present Phase 2 Results of AKCEA-APOCIII-L(Rx) in PR Newswire

Aug 13, 2020

07:07AM EDT Akcea Announces New Pricing And Reimbursement Of WAYLIVRA In Germany RTTNews

07:01AM EDT Akcea Announces New Pricing and Reimbursement of WAYLIVRA(r) (volanesorsen) in PR Newswire

Aug 10, 2020

07:21AM EDT Citigroup Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $78 Benzinga

Aug 6, 2020

09:02AM EDT Morgan Stanley Maintains Underweight on Ionis Pharmaceuticals, Lowers Price Target to $54 Benzinga

Aug 5, 2020

07:50AM EDT Ionis Pharmaceuticals Q2 EPS $(0.23) Beats $(0.27) Estimate, Sales $146.00M Miss $148.87M Estimate Benzinga

07:47AM EDT Ionis Pharmaceuticals: Q2 Earnings Insights Benzinga

07:13AM EDT Ionis Pharmaceuticals Q2 Net Loss $32 Mln Or $0.23/shr Vs. Net Loss $1 Mln Or $0.01/shr Last Year RTTNews

07:02AM EDT Ionis reports second quarter 2020 financial results and recent business PR Newswire